Form 4: Upstream Bio CFO and COO, Michael Gray, Reports Stock Option Grant

Michael Gray, CFO and COO of Upstream Bio, Inc., reports the acquisition of stock options.

Summary

• Michael Gray, the CFO and COO of Upstream Bio, Inc., filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Gray on February 6, 2025.
• The stock options give Gray the right to buy 195,000 shares of Upstream Bio's common stock at an exercise price of $8.53 per share.
• The options vest in 48 equal monthly installments starting February 6, 2025, contingent upon Gray's continued service.
• Allison Ambrose is appointed as a substitute attorney-in-fact for Michael Paul Gray.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of stock options is a standard practice and suggests confidence in the executive and the company's future.

Positives

• The grant of stock options to a key executive like the CFO and COO can be seen as an incentive to align their interests with the company's long-term success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies often use similar vesting schedules (e.g., monthly over 4 years) to retain key personnel.
• The size of the grant (195,000 shares) would need to be compared to grants at peer companies to assess its relative magnitude.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the CFO and COO to work towards increasing shareholder value.

Key Dates

Keywords

Form 4, Stock Options, Beneficial Ownership, Upstream Bio, Michael Gray, CFO, COO